바이오테크 보도자료
-
- KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
- KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly ser...
- 2022년 07월 07일
-
- Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
- Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a w...
- 2022년 07월 06일
-
- Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
- The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflamma...
- 2022년 07월 06일
-
- Top Sales Engagement Software Apps Industry Report: Japan and South Korea are Expected to secure USD 1.8 Bn and 1.1 Bn By 2032: Report Fact.MR
- According to a recent Fact.MR study, the global sales engagement software market is expected to hold a value of USD 7.4 Billion in 2022. Valued at USD 5 Billion in 2021, the market registered a Y-o-Y growth ...
- 2022년 07월 05일
-
- Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills
- With the realization of the first successful customer fills, Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has reached another milestone at its new clinical manufacturi...
- 2022년 07월 05일
-
- SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China
- A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific COVID-19 inactivate...
- 2022년 07월 05일
-
- VOOPOO Unveils 3 New Products, Telling Story of Its 8-year Entrepreneurship Journey in 30 Minutes
- VOOPOO’s 2022 “More Than Infinity” virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connecti...
- 2022년 07월 05일
-
- Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to
- Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, de...
- 2022년 07월 01일
-
- Quorum Software Announces Next Generation Planning and Economics Partnership with Schlumberger
- Quorum Software (Quorum), a global software leader dedicated to the energy industry, announced today that it has entered into an agreement with Schlumberger to jointly integrate Quorum’s industry-leading Pla...
- 2022년 07월 01일
-
- Medidata Announces Rapid Expansion of its Sensor Cloud Network with the Addition of 10 Health Technology Innovators
- Medidata, a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network. AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, I...
- 2022년 07월 01일
-
- MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis
- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency f...
- 2022년 06월 30일
-
- Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
- Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT...
- 2022년 06월 28일
전시회
